CDCA7L and Mechanisms of Increased Male Bias in Glioma

Karlyne Reilly, Ph.D.

The Geneva Foundation
Tacoma WA 98402

May 2016

Annual Report

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
We are proposing to study CDCA7L in an NF1 mutant model of astrocytoma and glioblastoma and neurotransmitter levels in NF1 mutant brains, comparing males and females. The results of this work can be used to develop additional hypotheses on whether a "yin-yang" relationship exists in males and females between risk for brain cancer and risk for depression, or other learning and social dysfunctions. Developing new treatments for gliomas and learning/social dysfunction through a better understanding of the basic biology will benefit both male and female NF1 patients in the long term.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2. Keywords</td>
<td>4</td>
</tr>
<tr>
<td>3. Accomplishments</td>
<td>4</td>
</tr>
<tr>
<td>4. Impact</td>
<td>6</td>
</tr>
<tr>
<td>5. Changes/Problems</td>
<td>7</td>
</tr>
<tr>
<td>6. Products</td>
<td>7</td>
</tr>
<tr>
<td>7. Participants &amp; Other Collaborating Organizations</td>
<td>7</td>
</tr>
<tr>
<td>8. Special Reporting Requirements</td>
<td>NA</td>
</tr>
<tr>
<td>9. Appendices</td>
<td>NA</td>
</tr>
</tbody>
</table>
1. Introduction

CDCA7L encodes the R1 transcription factor that is known to cooperate with Myc in transcriptional regulation, as well as repress the expression of MAOA and MAOB that are important regulators of catecholamines in the brain. We have shown that CDCA7L stimulated the growth of male astrocytic tumor cells and astrocytes, but has little to no effect on female astrocytic tumor cells and astrocytes. Males are at a greater risk for brain tumors and females are at a greater risk for depression that can be linked to changes in catecholamine levels. We have therefore hypothesized that CDCA7L may have different molecular propensities in males and females and are examining the role of Chr Y-specific epigenetic modifiers in affecting CDCA7L mode of action. NF1 patients are at a greater risk for both astrocytoma/glioblastoma and depression, so we are particularly interested in whether NF1 mutations affect the molecular function of CDCA7L and whether sex-specific treatments may be more effective for treating these complications of NF1. The goal of this project is to better understand regulation of CDCA7L expression, to characterize a new mouse mutant of Cdca7l, to look at the effect of Cdca7l loss on Nf1 tumorigenesis in male and female mice, and to examine the effect of Cdca7l loss on brain development, astrocyte phenotypes, and catecholamine levels.

2. Keywords
Neurofibromatosis type 1
CDCA7L
astrocytoma
glioblastoma
MAO
catecholamines
sex differences
mouse models

3. Accomplishments

Major Goals and Accomplishments:
In the previous year, we accomplished the following according to the task laid out in the SOW:

1) Establish maintenance colonies for C57BL/6N-Cdca7l-/-, C57BL/6J-Nf1-/-;Trp53-/-cins, C57BL/6J-Nf1-/-, and C57BL/6J-beta-actin-Cre-ERT for breeders needed in Task 2, 3, 4, and 5. We continue to maintain colonies of mutant mice as described in the Statement of Work. Because the original mutation in Cdca7l (Fig 1B) was found to be a hypomorph, we crossed the mice to ACT-FLPe mice to generate a floxed allele (Fig 1C), and crossed to CMV-Cre mice to generate an allele missing exons 5 to 9, expected to be a null allele (Fig 1D). We have confirmed the rearrangement of the null allele (Fig 1D) using PCR primers within the construct. Our efforts to confirm that there is no expression from the null allele have given us uninterpretable results thus far, possibly due to overlapping gene transcripts in the region. We continue to test new primer sets and antibodies to resolve this issue. We are currently sequencing the genomic DNA through the region to confirm the rearrangement is as we expect.

2) Establish expression pattern of Cdca7l in males and females during brain development using
a LacZ insertion reporter. (Months 3-6)
We began this task using the hypomorph allele in the previous reporting period, and will complete this task, once the sequencing described under Task 1 is completed.

3) Determine null and heterozygous Cdca7l mutant phenotype. (Months 3-21)
We have intercrossed the Cdca7l mice heterozygous for the null allele (Fig 1D) and have gotten null/null mice, suggesting the mutation is not embryonic lethal. In crosses of Cdca7lnull/+ X Cdca7lnull/+, 50% of progeny were Cdca7lnull/+, 29% of progeny were wild type, and 21% of progeny were Cdca7lnull/null. We have established an aging cohort of 10 males and 10 females each for Cdca7lnull/null and Cdca7lnull/wt along with wild-type littermates and are aging these to look for any obvious differences in lifespan or behavior. The oldest of these mice is currently 6.5 months old and no obvious phenotypes have been observed yet. We also euthanized 3 males and 3 females each for Cdca7lnull/null and Cdca7lnull/wt along with wild-type littermates at 9 weeks of age and surveyed all organs. No clear differences have been detected yet and we are still awaiting detailed review by our veterinary pathologist. Because we have not detected a postnatal phenotype yet, we will wait to collect the prenatal timepoints until the postnatal timepoints are thoroughly analyzed.

4) Test the hypothesis that reduced levels of Cdca7l inhibit brain tumors in NPcis mice (Months 7-34)
We are beginning to intercross the Cdca7l-null mice with the NPcis mice. We expect to finish these crosses in the next few months, and then age progeny up to 1 year. In the past year we have tested whether stable knockdown of CDCA7L in human glioblastoma cell lines inhibit growth in vivo by subcutaneous injection into athymic mice. Knockdown of CDCA7L in male U118MG cells completely blocked growth in vivo (Fig 2A), whereas knockdown in female U87MG cells led to much faster growth (Fig 2B).

5) Identify overlap of SNPs with putative CDCA7L regulatory regions. (Month 1-2)
This task was mostly completed in the previous reporting period. Given the increasing availability of human ENCODE data on transcription factor binding sites, we are reanalyzing the sites we originally identified. We expect to complete this task this summer.

6) Determine haplotypes of existing BAC libraries and human cell lines. (Months 3-4)
Due to advances in CRISPR technology, we are planning to test whether direct mutation of transcription factor binding sites in cell lines and looking at CDCA7L expression is a better approach than engineering BAC luciferase reporters. We will be conducting pilots this summer to decide whether to
switch our approach or keep the approach as described in Tasks 6-7.

7) Engineer and test BAC luciferase reporters for CDCA7L regulation by the CDCA7L-RAPGEF5 intergenic region. (Months 5-10)
   See Task 6

8) Test candidate trans-acting regulatory factors in the control of CDCA7L expression. (Months 11-15)
   We will initiate this task once Tasks 6-7 are complete, or we have tested regulatory regions using CRISPR technology.

9) Examine the interaction of changing Cdca7l levels with Nf1 mutation on brain phenotypes, catecholamine levels, and response to dopamine pathway therapeutics (months 3-9 and month 21-26)
   We will collect this data as soon as the sequencing results are completed as described in Task 1.

Opportunities for Training and Professional Development:
   This award has supported the training of one post-doctoral fellow, Dr. Min-Hyung Lee. During this reporting period, Dr. Lee presented his work at the Children's Tumor Foundation 2015 NF Research Symposium, giving him opportunities to learn from and network with leaders in the NF field. Dr. Lee moved to another position midway through this reporting period, so travel and training funds have been reserved for his replacement, Mr. Mackenzie Silverman (see (5) Changes/Problems below for more details).
   In addition, Dr. Lee and I meet several times a week to go over experimental design. We are currently revising his manuscript on the role of CDCA7L in brain cancer, and I expect the incoming post-baccalaureate fellow, Mr. Silverman, to help complete the final experiments needed for resubmission.

Dissemination of Results:
   Dr. Lee has presented his work on CDCA7L at the Children’s Tumor Foundation 2015 NF Research Symposium as described under (6) Products. We are revising a manuscript based on his findings so far on the sex-specific activity of CDCA7L. As noted under Major Goals and Accomplishments, most of the major goals of the project are still in the early phases, in part due to changes in personnel this reporting period (see (5) Changes/Problems below for more details) and are not ready to be publically disseminated.

Plans for Next Reporting Period:
   In the next reporting period we will finish characterization of the Cdca7l-null allele. If necessary, we will cross the Cdca7l-flox allele to Cre to get a true null allele (Fig 1E). We will generate NPcis;Cdca7l mutant mice for aging studies and generate Nf1;Cdca7l mutant mice to collect brains for catecholamine analysis.
   We will test whether CRISPR can be used to mutate regulatory regions in human and mouse cells to look at changes in CDCA7L expression, and whether we can adequately quantify CDCA7L directly or whether cloning of the luciferase gene into the CDCA7L locus is necessary to measure expression levels. Depending on the results of these pilots, we will test regulatory regions either using CRISPR or BAC-luciferase reporters.
   Depending on the results of the testing of regulatory regions, we will begin depletion of transcription factors that bind to the regulatory regions of interest.
   We expect that we will need to request a no cost extension in the next reporting period.

4. Impact:
   We have nothing new to report this period, beyond what was stated in the previous annual report.

5. Changes/Problems:
Dr. Min-Hyung Lee, the post-doctoral fellow dedicated to the project, left the laboratory November 1, 2015 to start a second post-doctoral fellowship with the FDA and pursue his interests in the regulatory field. Because of the Center for Cancer Research’s policy of only hiring post-doctoral fellows for a minimum of 3 years, it was not possible to directly replace Dr. Lee. I have been working with the Geneva Foundation on different mechanisms to fill this position. I have recently hired a post-baccalaurate fellow, Mr. Mackenzie Silverman, for the upcoming year who will begin work in early June, 2016. Many of the molecular biology tasks have been on hold until the new fellow is in place. Due to this delay in hiring, plus the time it will take Mr. Silverman to get up to speed on the projects, I anticipate I will need to request a no cost extension. Because Mr. Silverman’s salary and benefits are significantly less that Dr. Lee’s, I am working to hire an additional post-baccalaureate fellow with complimentary experience to work with Mr. Silverman on the project.

While we have generated the mouse Cdca7l-null allele that was a difficulty during the last reporting period, testing the expression in these mice has led to results that are difficult to explain, and have caused us to resequence through the genomic region of the rearrangement. Some of the tasks related to these mice have been held back until we have these results. We have also generated the flox allele for Cdca7l and if the “null” allele has rearranged to give an unexpected result by sequencing, we will cross the floxed allele to Cre to generate an additional form of the null allele, although one that lacks the LacZ reporter gene (Fig 1E).

Due to advances in CRISPR technology in recent years, we will investigate whether directly mutating regulatory DNA sequences in cell lines and measuring CDCA7L expression directly is a better method for Tasks 6-7 than engineering BAC luciferase reporters. Depending on pilot experiments, we will either switch to CRISPR technology, or keep the original method as outlined in the statement of work. Mr. Silverman will begin this work when he joins the lab in June. If applicable, we will request prior approval prior to implementing any change to the Statement of Work.

6. Products:
Conference Papers and Presentations:

Poster Presenter: Dr. Min-Hyung Lee  
Title: CDCA7L is a gender-specific modifier of astrocytoma and glioblastoma  
Date: 6/7/16  
Location: Children’s Tumor Foundation 2015 NF Conference, Monterey, CA

Oral Presenter: Dr. Karlyne Reilly  
Title: Sex bias in astrocytoma/glioblastoma: CDCA7L as a male-specific oncogene  
Date: 4/18/16  
Location: Understanding the Sex Bias in Disease Symposium, NIH, Bethesda, MD

Research Materials: 
Cdca7l mutant mouse allelic series: hypomorph, floxed allele, null allele

7. Participants and Other Collaborating Organizations:

Name: Min-Hyung Lee  
Project Role: Post-doctoral Fellow  
Researcher Identifier:  
Nearest person months worked: 5  
Contribution to the project: Dr. Lee has been working on the mechanism of how CDCA7L functions in males and females. He tested the growth of glioblastoma cells with CDCA7L knockdown in athymic mice. Dr. Lee’s salary is provided by this award. Dr. Lee left the project on November 1, 2015 to start a fellowship at the FDA.

Name: Karlyne Reilly  
Project Role: Principal Investigator  
Researcher Identifier: 0000-0001-9109-4409
Nearest person months worked: 3
Contribution to the project: Dr. Reilly has monitored the mouse colony, determining which breeders to set-up and which mice to euthanize for analysis. She has also managed the budget and supervised Dr. Lee and Mr. Tuskan. Dr. Reilly’s salary is provided by the National Cancer Institute.

Name: Robert Tuskan
Project Role: Technician
Researcher Identifier:
Nearest person months worked: 2
Contribution to the project: Mr. Tuskan has prepared tail DNA from the Cdca7l mouse colony and genotyped them for whether they carry the Cdca7l mutation. Mr. Tuskan is designing primers to sequence the Cdca7l allele construct. Mr. Tuskan also helps to monitor the budget and places all orders for the grant. Mr. Tuskan’s salary is provided by the National Cancer Institute.

Organization Name: Leidos
Location: Frederick, MD
Project Role: Animal Technical Support and Histology Technical Support
Nearest person months worked: 2
Contribution to the project: The animal technical support staff at NCI, Frederick monitor the health of the mouse colony, set up breeders, tail clip mice, and euthanize mice under Dr. Reilly’s instruction. The histology technical support at NCI, Frederick, euthanize and dissect mice as needed for the project and process tissues for histology. Slides are sent to Dr. Reilly for review.

Changes in active support: Nothing to Report.